Literature DB >> 3926326

Association of decreased natural and antibody-dependent cellular cytotoxicity and production of natural killer cytotoxic factor and interferon in neonates.

M P Nair, S A Schwartz, M Menon.   

Abstract

Cord blood lymphocytes (CBL) were compared with adult peripheral blood lymphocytes (a-PBL) for their: (i) natural killer (NK) and antibody-dependent cellular cytotoxic (ADCC) activities, (ii) target-binding capacity, (iii) ability to induce soluble natural killer cytotoxic factor (NKCF), (iv) interferon (IFN)-, interleukin 2 (IL-2)-, and lectin-induced augmentation of NK activity, and (v) ability to produce IFN against tumor targets in vitro. CBL depleted of adherent cells and Percoll-separated, NK-enriched subpopulations demonstrated significantly lower NK, ADCC, and target-binding activities compared to a-PBL. CBL produced significantly lower levels of NKCF directed against K562 tumor targets in comparison with a-PBL. Although the NK activity of CBL was not stimulated by either IFN or IL-2 to the same levels shown by a-PBL, the percentage enhancement of cytotoxicity of CBL by IFN and IL-2 was greater than that of a-PBL. Lectin-induced enhancement of cytotoxicity was significantly greater for CBL in comparison with a-PBL. Further, the ability of CBL lymphocytes to produce IFN-gamma in vitro against K562 target cells was significantly lower than that of adult PBL. These studies suggest an association between decreased NK, ADCC, and target-binding activities, induction of NKCF and IFN production by CBL, and increased susceptibility of neonates to infection.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3926326     DOI: 10.1016/0008-8749(85)90093-0

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  10 in total

1.  Immunoregulatory dysfunctions in type I diabetes: natural and antibody-dependent cellular cytotoxic activities.

Authors:  M P Nair; E W Lewis; S A Schwartz
Journal:  J Clin Immunol       Date:  1986-09       Impact factor: 8.317

Review 2.  Roles of interferon produced in physiological conditions. A speculative review.

Authors:  V Bocci
Journal:  Immunology       Date:  1988-05       Impact factor: 7.397

3.  Reversal of human immunodeficiency virus type 1 protein-induced inhibition of natural killer cell activity by alpha interferon and interleukin-2.

Authors:  M P Nair; S A Schwartz
Journal:  Clin Diagn Lab Immunol       Date:  2000-01

4.  Natural cytotoxicity in the neonate: high levels of lymphokine activated killer (LAK) activity.

Authors:  D Montagna; R Maccario; A G Ugazio; G Mingrat; G R Burgio
Journal:  Clin Exp Immunol       Date:  1988-01       Impact factor: 4.330

5.  Modulation of the cell-mediated immune function by interferon alpha, beta or gamma can partially reverse the immunosuppression induced by human T-cell leukemia virus I in human cord blood cultures.

Authors:  C D'Onofrio; C D Pesce; T Fontana; F Ciprani; E Bonmassar; R Caliŏ
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

6.  Correlation of susceptibility of immature mice to fungal infection (blastomycosis) and effector cell function.

Authors:  A Ganer; E Brummer; D A Stevens
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

7.  Differential effects of human immunodeficiency virus type 1 envelope protein gp120 on interferon production by mononuclear cells from adults and neonates.

Authors:  M P Nair; K C Chadha; I Stadler; A Sweet; S A Schwartz
Journal:  Clin Diagn Lab Immunol       Date:  1995-07

8.  Activation of natural killer cells in newborn piglets by interferon induction.

Authors:  C E Lesnick; J B Derbyshire
Journal:  Vet Immunol Immunopathol       Date:  1988-03       Impact factor: 2.046

Review 9.  Dysregulated Mucosal Immunity and Associated Pathogeneses in Preterm Neonates.

Authors:  Maame Efua S Sampah; David J Hackam
Journal:  Front Immunol       Date:  2020-05-15       Impact factor: 7.561

10.  Depression of early phase of HTLV-I infection in vitro mediated by human beta-interferon.

Authors:  C D'Onofrio; C F Perno; P Mazzetti; G Graziani; R Calio'; E Bonmassar
Journal:  Br J Cancer       Date:  1988-05       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.